Anoro Ellipta (umeclidinium/vilanterol 62.5 mcg/25 mcg)

Anoro Ellipta (umeclidinium/vilanterol 62.5 mcg/25 mcg) is a treatment for chronic obstructive pulmonary disease (COPD) that combines a long-acting muscarinc agent (LAMA) or anticholinergic, umeclidinium, and a long-acting beta2-adrenergic agonist (LABA) medicine, vilanterol.

Anticholinergic and LABA medicines work by helping the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can occur when the muscles around the airways tighten, making it difficult to breathe.

Anoro Ellipta is a maintenance treatment; it is typically taken every day to help manage and control ongoing COPD symptoms. It cannot replace a rescue inhaler to treat severe, sudden COPD symptoms or COPD flare-ups.

What are the ingredients in Anoro Ellipta?

The active ingredients in Anoro Ellipta are umeclidinium and vilanterol

How does Anoro Ellipta work?

The medicines combined in Anoro Ellipta are both long-term treatments to help improve airflow and breathing for people with COPD. The lung damage caused by COPD can cause a person’s airways to become blocked in different ways. Irritation and swelling in the airways can cause them to become narrowed and make it difficult for enough air to pass through. Bronchospasms occur when the irritation causes the muscles that surround the airways to tighten up, and this can also cause the airways to narrow.
Vilanterol is a LABA, while umeclidinium is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic. Both of these drugs work in different ways to keep the muscles that surround the airways from tightening.

What are the possible side effects of Anoro Ellipta?

In clinical trials of Anoro Ellipta, the most common adverse reaction were pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, and chest pain. People with asthma who take LABA medicines, such as vilanterol (one of the active ingredients in Anoro Ellipta), have an increased risk of death from asthma problems. It is not known if LABA medicines such as vilanterol increase the risk of death in people with COPD.

This is not an exhaustive list of all potential side effects of Anoro Ellipta. Talk to your healthcare provider or pharmacist for further information.

Things to know about Anoro Ellipta

Anoro Ellipta should not be used if you have a severe hypersensitivity to milk proteins or if you have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the other ingredients in this medication.

Before using Anoro Ellipta, it’s important to tell your healthcare provider about all of your medical conditions, including if you:

  • Have heart problems.
  • Have high blood pressure.
  • Have seizures.
  • Have thyroid problems.
  • Have diabetes.
  • Have liver problems.
  • Have eye problems such as glaucoma. Anoro Ellipta may make your glaucoma worse.
  • Have prostate or bladder problems, or problems passing urine. Anoro Ellipta may make these problems worse.
  • Are allergic to any of the ingredients in Anoro Ellipta, any other medicines, or food products.
  • Are pregnant or planning to become pregnant, or if you are breastfeeding. It is not known if Anoro Ellipta may harm your unborn baby. It is not known if the medicines in Anoro Ellipta pass into your milk and if they can harm your baby.

Dosing information

Anoro Ellipta is typically administered as 1 oral inhalation once daily. Anoro Ellipta should be used at the same time every day, and should not be used more than 1 time every 24 hours.

For more information, read the full prescribing information of Anoro Ellipta.

Written by: Kristine Zerkowski | Last reviewed: April 2018.
View References
  1. Anoro Ellipta [Prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; October 2017.